ALLISON INQUIRY
Rule 25 Exhibits
Inquiry Rule 25 permits the Chairperson and Inquiry Counsel to jointly agree to admit materials to the Inquiry Record.
This page lists the Exhibits entered under Rule 25.
R25-A Rule 25 Application to admit evidence concerning the Drug Test used for the Covid-19 vaccines.
R25-1 Food and Drug Regulations, C.R.C, c. 870 section C.08.002 as it read in 2020 and up to March 18, 2021 (Pre-Covid Drug Approval Test).
R25-2 Interim Order exempting Covid-19 vaccines from the regular drug approval process and creating a substitute process for their approval. This Interim Order was made on September 16, 2020 pursuant to section 30.1 of the Food and Drugs Act, R.S.C., 1985, c. F-27 (Interim Order).
R25-3 Order in Council dated October 3, 2020, extending the exemption of Covid-19 vaccines from the regular drug approval process, and continuing the substitute process for their approval. Canada Gazette, Part I, Volume 154, Number 40: Orders in Council.
R25-4 Regulation SOR/2021-45 which on March 18, 2021, incorporated the provisions of the Interim Order, with some minor changes, into the Food and Drug Regulations, C.R.C., c. 870.
R25-5 Regulation SOR/2024-238 sections 24-40, which on November 29, 2024, amended the Food and Drug Regulations. The main change was to replace the term designated COVID-19 drug with the term public health emergency drug.
R25-6 List of Conditions for public health emergency drugs. The only condition on the list is Covid-19. This enables Covid-19 vaccines to remain exempt from proving safety and efficacy when seeking approval for use.
R25-7 Guidance for market authorization requirements for COVID-19 vaccines. October 29, 2021 Health Canada policy document.
Watch The Latest Press Conference
- July 9th, 2026
- Parliamentary Press Gallery
- Ottawa, Ontario
